Eczema secretary tel: 020 7188 0844
Psoriasis secretary tel: 020 7188 6417
Richard Woolf is a consultant dermatologist at the St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust. His key clinical interest is in medical dermatology, working across large specialist eczema and psoriasis services. He also works in the general dermatology and skin cancer screening services.
Richard is the clinical lead for medical dermatology at the St John's Institute of Dermatology, starting September 2021. In addition, Richard is involved in the operational delivery of the eczema and psoriasis services and has led on service redesign and innovation.
Richard has an interest in clinical research. During his dermatology training he completed a MRC-funded clinical research training fellowship studying innate immunology in the skin, with the award of PhD in skin immunobiology (2015, King's College London). After this he was awarded an NIHR academic clinical Lectureship at the St John's Institute of Dermatology and King's College London. In his current consultant role Richard is a principal investigator and sub-investigator on multiple trials in atopic dermatitis and psoriasis.
- Atopic dermatitis (eczema)
- Clinical trials
- General dermatology
- Skin cancer screening
Education and training
- Speciality Certificate in Dermatology, Royal College of Physicians (London, 2016)
- Doctor of Philosophy (PhD) in Immunobiology, King's College London (London, 2015)
- Membership of the Royal College of Physicians (MRCP), Royal College of Physicians (London, 2009)
- MBChB, Degree in Medicine and Surgery, University of Bristol (Honours, 2006)
- Bachelor of Science in Cancer Biology and Immunology, University of Bristol (First Class Honours, 2003)
- Medical Research Council (UK) Clinical Research Training Fellowship [MR/K002627/1] (2012)
Richard works with his consultant colleagues (Professor Jonathan Barker, Professor Catherine Smith, Dr Andrew Pink, Dr Satveer Mahil) in the skin therapy research unit to deliver a large range of phase 2 to 4 commercial and non-commercial trials in atopic dermatitis, psoriasis and related conditions.